HEPP Report: Infectious Diseases in Corrections, Vol. 6 No. 4 by HIV & Hepatitis Education Prison Project
University of Rhode Island
DigitalCommons@URI
Infectious Diseases in Corrections Report (IDCR)
2003
HEPP Report: Infectious Diseases in Corrections,
Vol. 6 No. 4
HIV & Hepatitis Education Prison Project
Follow this and additional works at: http://digitalcommons.uri.edu/idcr
This Article is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Infectious Diseases in
Corrections Report (IDCR) by an authorized administrator of DigitalCommons@URI. For more information, please contact
digitalcommons@etal.uri.edu.
Recommended Citation
HIV & Hepatitis Education Prison Project, "HEPP Report: Infectious Diseases in Corrections, Vol. 6 No. 4" (2003). Infectious Diseases
in Corrections Report (IDCR). Paper 44.
http://digitalcommons.uri.edu/idcr/44
As guidelines for the diagnosis, evaluation and
treatment of chronic hepatitis C virus (HCV)
emerge in the community at large, correctional
medical communities are wrestling with the chal-
lenge of establishing an appropriate and consis-
tent response to an epidemic that disproportion-
ately affects incarcerated populations.
Controversies regarding the management of HCV
are brought to a head in jails and prisons, where
there is a high prevalence of disease (12-35%
according to Centers for Disease Control (CDC)
estimates1) and a legal obligation to provide
access to medical care. 
Two recent publications, the MMWR
Recommendation and Report on the Prevention
and Control of Infections with Hepatitis Viruses in
Correctional Settings1 and the 2002 NIH
Consensus Statement on the Management of
Hepatitis C2 begin to frame the key issues facing
correctional health services. Soon after these
reports were published, several hundred correc-
tional administrators, correctional physicians,
hepatologists, infectious disease specialists, pub-
lic health professionals and other interested par-
ties met in San Antonio for a conference on the
management of HCV infection in corrections. In
the aftermath of the conference, data shared at
the meeting and various approaches taken by dif-
ferent systems have been discussed and debat-
ed. It should be noted that most of what was dis-
cussed at this conference did not address the
unique challenges of HCV management in jail cor-
rectional settings.
While controversies abound concerning the man-
agement of HCV in corrections, the discussion
was notable for several areas of emerging con-
sensus. Perhaps the most noteworthy was the
agreement that all systems need to develop and
establish a systematic approach to the manage-
ment of HCV infection.3
In this article, I review existing HCV management
controversies from the correctional perspective,
document an emerging consensus among correc-
tional practitioners, and provide suggestions for
future directions in HCV care.
Impact of Disease
Controversy: While the high prevalence of dis-
ease in corrections is widely accepted, debate
has centered on the clinical significance of infec-
tion to correctional health care systems. Given
that HCV appears to lead to morbidity and mortal-
ity in only a minority of infected individuals, and for
that minority, progression to fibrosis, cirrhosis and
death is expected to take decades, some argue
that the immediate impact to the clinical health of
currently incarcerated inmates should be minimal.
Emerging Consensus: Despite the very recent
recognition of the epidemic, available information
suggests that the HCV epidemic among the incar-
cerated is decades old. Data from liver biopsies in
several correctional systems (including Virginia4
and Louisiana5) show that many patients already
have advanced fibrosis and cirrhosis, consistent
with longstanding infection. In other facilities, HCV
infection has emerged as a leading cause of in-
custody death.6,7 End-stage liver disease is now
recognized as the leading cause of death in HIV-
positive populations, especially in those patients
who are responsive to HAART.8 Given the preva-
lence of HCV in corrections and considering pro-
jections from the CDC regarding anticipated
cases of cirrhosis, end-stage liver disease and
hepatocellular carcinoma, correctional communi-
ties should anticipate rising morbidity and mortali-
ty from HCV-related disease in the near term.
Recommendation:In order to better understand
the HCV problem in the correctional setting, more
data need to be collected and shared. Wide vari-
ations in rates from state to state and even from
facility to facility are likely. Collecting national and
facility-specific data is essential in order to adapt
national guidelines and recommendations to local
HCV management.
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Infectious Diseases in Corrections
Developing a Systematic Approach to Hepatitis
C for Correctional Systems: Controversies and
Emerging Consensus
By Scott Allen, M.D.*, Medical Director, Rhode Island Department of Corrections
Continued on page 2
Correctional health care systems, perhaps in
conjunction with NIH, CDC, and local or
regional departments of health should consid-
er developing a central database similar to
existing cancer and HIV/AIDS registries.
Correctional health care workers should be
encouraged to report and circulate experi-
ence and outcome data, cost-effectiveness
data and novel strategies for the diagnosis
and management of HCV infection through
peer-reviewed journals, correctional newslet-
ters, and conferences.
Screening
Controversy: Given the high prevalence of
HCV infection in correctional settings, some
have argued in favor of universal screening,
while others believe targeted screening of
inmates is the right approach.
Emerging Consensus: Both universal and
targeted screening methods have been used
in correctional systems. In Indiana, the legis-
lature recently implemented mandatory
screening of all inmates for HCV and HIV.
Testing is performed by the Indiana
Department of Health and requires several
blood samples from each inmate; as a result,
correctional health officials had to adjust
intake procedures after the legislation was
passed.9
Other states use targeted approaches. In
Wisconsin, an innovative risk-based assess-
ment was performed to target individuals for
hepatitis screening.10 Using the screening cri-
teria of testing all inmates with a history of
injection drug use (IDU), hepatitis B virus
infection, or elevated ALT, 90.8% of individu-
als with HCV were identified, while only a
quarter of the population (26.8%) required
testing. Comparison of expected costs based
on 8,000 inmates/year at a reception center
with a HCV prevalence of 13.2% (probably a
low figure compared to other states, DOC offi-
cials admit) predicted an estimated $100,000
in savings on blood tests per year. 
The new guidelines published by the CDC
suggest that all inmates be questioned
regarding risk factors (see box) for HCV infec-
tion during their entry medical evaluations,
and all inmates reporting risk factors for HCV
should be tested. As the specificity of any test
is a function of prevalence, the CDC further
recommends that the sensitivity of risk-factor
based screening be periodically determined,
and that expanded testing be considered (i.e.
to patients denying risk factors) when risk fac-
tor prevalence, including IDU, is > 75% and
prevalence of infection among those who
deny risk factors is also high (>20%).1
Recommendation:The period of incarcera-
tion provides an important window of opportu-
nity to diagnose and educate those at risk for
hepatitis C. In addition to providing an oppor-
tunity for the evaluation and treatment of
those with HCV, the identification of infected
individuals has the potential to reduce subse-
quent transmission in the community. At a
minimum, correctional facilities should have a
systematic plan for screening based on risk
factors and disease prevalence in the facility.
Evaluation
Controversy: While there is widespread
agreement that liver biopsy can be a useful
tool to evaluate chronic HCV, the cost-effec-
tiveness of offering biopsies, or even requir-
ing biopsies is widely debated.
Emerging Consensus: There is general
agreement that patients with early stage dis-
ease, particularly those with stage 0-1 dis-
ease, can be counseled to defer treatment.
Therefore, liver biopsy may permit clinicians
to defer treatment in some cases, avoiding
unnecessary treatment and reducing the
overall cost of care. In Virginia, implementing
a management strategy for evaluating and
treating HCV that included liver biopsy was
found to be cost-effective. All inmates in the
Virginia Department of Corrections are
offered HCV testing, and those that test posi-
tive for HCV RNA are offered liver biopsy. The
Virginia strategy of triaging patients to care or
no care depending on liver biopsy results lim-
its treatment to inmates with "clinically signifi-
cant" disease and, according to official esti-
mates, saves almost $125,000 per 100
patients.4
Recommendation:I believe that liver biopsy
is an essential tool in evaluating a patient for
treatment. Although remote facilities may find
liver biopsy difficult to access, biopsy is help-
ful in counseling the patient on the status of
disease and the relative indication or con-
traindication for treatment. Given the data on
its cost-effectiveness and clinical utility, biop-
sy of potential candidates for treatment is rec-
ommended. In patients with infection caused
by genotypes 2 and 3, where 24-week cours-
es of treatment are associated with high
response rates, biopsy may be less impor-
tant.
Treatment
Controversy: Correctional health care
providers and administrators worry that liber-
al inclusion criteria to treatment will result in
an overwhelming demand for therapy.
Emerging Consensus: Legal and ethical
considerations make it inadvisable to provide
barriers to treatment simply to minimize the
cost impact to institutions. However, clinically
based strategies aimed at stratifying candi-
dates for therapy is defensible and advisable. 
Systematic approaches that take into consid-
eration a variety of factors, including the like-
lihood of progression to cirrhosis based on
clinical data and risk factors, allow for target-
ing high-risk patients for treatment. Most
practitioners are now selectively advising
medical treatment for those HCV-infected
inmates who are clinically appropriate and
who are anticipated to remain incarcerated
for the full course of treatment. 
"Clinically appropriate" patients include those
with stage 2, 3, and compensated stage 4
liver disease. Stage 1 rapid fibrosers (as
determined by serial liver biopsies) may also
be considered for treatment. Treatment can
safely be deferred in patients with stage 0-1
fibrosis, although the decision should be indi-
vidualized and based on an informed consul-
tation with the patient.
Institutions with clinically defensible system-
atic approaches - even those with liberal
inclusion criteria - end up treating only a per-
centage of those patients potentially eligible
for treatment. The vast majority of treatment
candidates will appropriately be deferred to
treatment after release due to short length of
incarceration. Of the remainder, a great pro-
portion will elect to defer treatment after bal-
anced informed consent based on early-
stage disease or documented slow progres-
sion. 
Recommendation: All correctional health
care programs should develop systematic,
evidence-based guidelines for HCV manage-
ment. Such guidelines, however, should
never supplant the clinical judgement of the
clinician, and decisions should always be
made in consultation with the patient. Given
the superior response rates of pegylated
interferon plus ribavirin vs. standard interfer-
on therapy plus ribavirin for treatment of
genotype 1, treatment with pegylated interfer-
on is recommended.11
Patients with Psychiatric
Illness and/or History of
Substance Abuse
Controversy: The correctional population
has a high prevalence of individuals with a
history of substance abuse and mental illness
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Those at risk for HCV include persons
who:
w injected drugs intravenously and
shared unclean injecting equipment; 
w received a clotting factor concentrate
produced before 1987; 
w were on long-term hemodialysis; 
w have evidence of chronic liver disease
including persistently abnormal ALT lev-
els; or 
w received a transfusion of blood or
blood components or an organ trans-
plant before July 1992. 
To read the complete report, go to
http://www.cdc.gov/mmwr/preview/
mmwrhtml/rr5201a1.htm.
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Dear Correctional Colleagues:
As I contemplate the April HEPP Report articles, I have come to the conclusion that we c uld
not have chosen two more controversial and current issues in health care today - the treatment
of HCV infection in prisoners and the administration of smallpox vaccine to health care pro-
fessionals. 
In the past, much of the controversy regarding HCV treatment was due to poor sust ined
response rates to therapy that is not only expensive, but also fraught with significant side
effects. Although potential side effects are still worrisome, combination therapy with pegylated
interferon and weight-based ribavirin now provides improved sustained response rates, mak-
ing therapy more attractive to both the patient and the provider. Approximately one third of
those infected with HCV in the U.S. cycle through the correctional system. We have a remark-
able opportunity to improve the health of the nation by screening, testing, counseling, and
when possible, providing treatment to the incarcerated.
In corrections, and elsewhere in health care, the very real issue is, how can we pay for this
effective, but expensive treatment? The answer is local, state, and federal funding, which there
is less of in recent months due to downward trends in the economy and the war in Iraq. We
must continue to educate our administrators and legislators to ensure that when funds become
available, they can be requested and allocated for effective HCV treatment. 
In this month's lead article, Dr. Scott Allen convincingly advocates for a systematic approach
to managing hepatitis C in corrections. Such an approach will vary among the varying correc-
tional jurisdictions and will be based on current and future resources. Despite the current
inability to treat every prisoner who has HCV infection, we should screen and test those who
may be affected and provide appropriate counseling regarding transmission to others, the
importance of avoiding alcohol, and the potential for future treatment options. 
In this month’s spotlight, Dr. Joe Bick outlines the threat faced by correctional facilities that
employ individuals who have received the smallpox vaccination, and reviews CDC guidelines
for preventing transmission while the inoculation site heals.
After reading this month's issue, you should be familiar with the issues surrounding the
approach correctional institutions are taking with HCV-infected inmates, as well as CDC guide-
lines for smallpox vaccination and the precautions that should be taken to minimize transmis-
sion of the vaccina virus while the inoculation site heals.
Sincerely yours,
David Paar
Letter from the Editor
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- two groups who have historically been
excluded from treatment or who have been
associated with poor treatment outcome.12
Emerging Consensus: Owing to the con-
trolled environment of the correctional setting,
the traditionally challenging patient groups -
those with histories of substance abuse
and/or mental illness - may find themselves in
one of the safer environments for therapy with
interferon and ribavirin. 
The contraindication to therapy for HCV infec-
tion in those with substance abuse was lifted
in the 2002 NIH consensus statement, follow-
ing a review of the published data regarding
efficacy of treatment of HCV in patients with
IDU and alcoholism.13 However, experts
agree that HCV treatment should be coupled
with substance abuse counseling and referral
for treatment. Sobriety is largely enforced in
the correctional setting, making it a more sta-
ble environment in which to contemplate med-
ical therapy for HCV infection. Stable psychi-
atric illness is no longer considered an
absolute contraindication to treatment with
interferon based therapies.
Psychiatric illness, and in particular depres-
sion, has historically been seen as a relative
contraindication to therapy given the potential
of treatment to cause depression.14 On the
order of a third of all patients treated with
interferon can be expected to develop symp-
toms of major depression.  In Rhode Island, in
a review of 90 patients treated with standard
IFN and ribavirin, 60% of the patients had a
history of mental illness, 44% had a history of
depression, 8% were diagnosed with psy-
chosis and 4% had a documented history of a
prior suicide attempt. Patients were stabilized
and cleared by the psychiatry team prior to
the initiation of therapy and followed closely
by the psychiatric team during therapy. No
patient had to discontinue therapy due to psy-
chiatric side effects.15
Recommendation: A history of substance
abuse is no longer a contraindication for treat-
ment of chronic HCV infection. Linking med-
ical therapy with referral to substance abuse
treatment, however, is a good idea. Still, the
absence of available substance abuse treat-
ment programs in a correctional setting
should not be used to justify withholding treat-
ment. Counseling should include discussion
of harm reduction (clean needle access
through provider prescriptions, needle
exchange programs and pharmacy purchas-
es, where available) in the event of relapse of
drug use post-treatment.
In facilities where mental health care is avail-
able, an effort should be made to coordinate
the evaluation and treatment of candidates
with both chronic HCV infection and mental
health problems. The close clinical follow up
available in correctional settings may provide
a safe environment for the treatment of HCV-
infected patients who also have a psychiatric
illness. While treatment of patients with unsta-
ble psychiatric illness remains contraindicat-
ed, patients who have clinically stable mental
illness may be safely treated. The decision
should be made on a case-by-case basis with
input from the patient, the medical provider
and the treating psychiatrist.
Cost
Controversy: High prevalence of HCV com-
bined with historically high utilization of med-
ical services among inmate patients have
c used legitimate concern among correction-
al health care administrators that the cost of
treatment could overwhelm already con-
strained correctional health care budgets.
Emerging Consensus:As previously stated,
systematic, clinical-based approaches (such
as those used by the Federal Bureau of
Prisons) can direct medical treatment to those
most likely to progress to cirrhosis and are
clinically and ethically justifiable. Within the
context of such approaches, only a minority of
patients ultimately receives treatment.16 In
Rhode Island, where one of the more inclu-
sive treatment protocols has been established
and the prevalence of HCV infection stands at
27%, less than 5% of HCV positive patients
are receiving treatment at any given time, and
the cost of HCV-related treatment is limited to
5% of the total healthcare budget.3
Recommendation: Systematic approaches
to screening, evaluation and treatment will
mitigate the high cost of HCV care in correc-
tional settings. However, the high prevalence
of HCV infection - a treatable disease - in the
context of an obligation to provide access to
care can still be expected to have a significant
impact on correctional budgets in the near
term. Continuing efforts to educate the legis-
latures, executive branches, public health
agencies and the broader community should
be encouraged.
Conclusion
While screening, evaluation and treatment
inclusion and exclusion criteria for HCV in
corrections will continue to be hotly debated,
ere is emerging consensus regarding some
aspects of HCV disease management. Chief
among them is the growing recognition that all
correctional systems will need to develop and
implement an evidence-based systematic
approach to the large numbers of patients
housed within correctional institutions in the
United States. As correctional systems move
forward in responding to this challenge, it is
essential that data regarding disease preva-
lence, morbidity and mortality and treatment
outcomes and cost-effectiveness be collected
and disseminated.
*DISCLOSURES: Nothing to disclose.
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Smallpox Alert in Jails and Prisons
While our nation's jails and prisons might appear to be a safe place
to be to avoid the potential health risks associated with smallpox,
this may not be the case. Many correctional employees serve as
reservists in the military, while others are being trained to diagnose
or treat individuals who are suspected of having smallpox. Both
groups are among those who may be vaccinated against smallpox,
which should be of concern to those providing health care to
immunocompromised inmates. Transmission of the virus used for
smallpox vaccination is a well-recognized phenomenon that can
lead to devastating consequences in those with underlying medical
disorders. This article is intended to provide a brief summary of what
those responsible for correctional health care need to know about
smallpox vaccination. Information that follows is based on recently
published Centers for Disease Control and Prevention (CDC) guide-
lines.1,2,3
Overview
Smallpox vaccine is made from live vaccinia virus and does not con-
tain variola virus, the causative agent of smallpox. Because vaccinia
viral replication and shedding occurs at the vaccination site, unin-
tended transmission can occur from as early as two days after vac-
cination until the scab separates from the skin two to three weeks
later. 
Replication of vaccinia virus can be enhanced among immunosup-
pressed patients. Except in the setting of an outbreak, smallpox vac-
cination is contraindicated for individuals with atopic dermatitis
(eczema) or other skin conditions that disrupt the epidermis; women
who are pregnant or who may become pregnant in the 28 days after
vaccination; and those immunosuppressed due to HIV infection,
autoimmune conditions, malignancy, radiation treatment, medica-
tions, or other immunodeficiencies. 
Persons with HIV infection might have an increased risk for severe
adverse reactions resulting from exposure to live-virus vaccines.
Because the HIV epidemic began after routine smallpox vaccination
ended in the 1970s, data are limited regarding the risks from vacci-
nation among HIV-infected persons.
On March 25, 2003, the CDC reported that among 25,645 civilians
who have been vaccinated, there have been three cases of myocar-
dial infarction, one of which resulted in death; two cases of angina,
and two cases of myopericarditis. Based upon this information, the
CDC added the recommendation that persons with known cardiac
disease such as cardiomyopathy, previous heart attack, angina, or
other evidence of coronary artery disease be temporarily deferred
from smallpox vaccination.
Transmission of Vaccinia Virus 
Vaccinia can be transmitted to others from an unhealed vaccination
site. Although nosocomial transmission of vaccinia from either
patients or health care workers to patients has been described,
transmission usually requires close interaction as would occur in a
household or dormitory setting. 
Cases arising from transmission through contact with a recently vac-
cinated person have resulted in either eczema vaccinatum (EV) or
inadvertent inoculation (when vaccinia virus is transferred from a
vaccination site to a second location on the body or to a close con-
tact), occurring 5-19 days after exposure to the source case. The
incidence of contact vaccinia in the 1960s was 2-6/100,000 first-time
vaccinations. Since there are many more people living today with
severe immunocompromising conditions, this may underestimate
the current risk.
Preventing contact transmission
The CDC's Advisory Committee on Immunization Practices (ACIP)
believes that optimal infection-control practices and appropriate site
care should prevent transmission of vaccinia virus. Those providing
direct patient care or who are in contact with inmates should keep
their vaccination site covered with gauze dressing to absorb exu-
dates; this dressing should be covered with a semipermeable mem-
brane to minimize the risk of transmission. The dressing should also
be covered by a layer of clothing until the scab separates, which may
take 14-21 days. Dressings used to cover the site should be
changed frequently to prevent maceration and accumulation of exu-
dates. 
Since transmission occurs through contact with the vaccination site,
the most critical measure in preventing contact transmission is con-
sistent hand hygiene with antimicrobial soap and water or an
approved alcohol-based hand-rub (one that contains >60% alcohol)
aft r any contact with the vaccination site or contact with materials
that have come into contact with the site. 
The CDC recommends that hospitals provide a program in which
designated staff (available 24 hours a day) assess the dressings of
all vaccinated health care workers daily before shifts begin, deter-
min  if dressings need changing, and change the dressing as need-
ed. In correctional settings, designated personnel may be responsi-
ble for assessing vaccination sites of correctional officers. These
designated staff should assess the vaccination site for local reac-
tions and for vaccine take, reinforce education regarding the need
for meticulous hand hygiene, and record and report serious adverse
events after vaccination. When feasible, staff responsible for dress-
ing changes for teams should be vaccinated, but having nonvacci-
nated staff change dressings is acceptable. All persons handling
b ndages should observe contact precautions.
Administrative Leave for Vaccinated Health Care Workers
The ACIP recommends that administrative leave is not routinely
required for newly vaccinated health care personnel unless they are
physically unable to work because of systemic signs and symptoms
of illness; have extensive skin lesions that cannot be covered ade-
qu tely; or are unable to adhere to the recommended infection-con-
trol precautions. However, the CDC expects that as many as 30% of
the nation's hospitals may opt out of the voluntary immunization pro-
gram because of concerns about health risks to those being vacci-
nated and the potential transfer of vaccinia to vulnerable popula-
tions. Each correctional system should take these issues into
acc unt when making a decision concerning administrative leave or
reassignment. 
Adverse Events of Vaccination
Adverse reactions are usually self-limited and include fever,
headache, fatigue, myalgia, chills, local skin reactions, nonspecific
rashes, erythema multiforme, lymphadenopathy, and pain at the vac-
cination site. Adverse reactions that might require further evaluation
or treatment include inadvertent inoculation, generalized vaccinia
(GV), eczema vaccinatum (EV), progressive vaccinia (PV), postvac-
cinial central nervous system disease, and fetal vaccinia. 
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Persons with PV, EV, and severe GV or inadvertent inoculation might
benefit from therapy with vaccinia immune globulin (VIG) or cido-
fovir, available from the CDC under Investigational New Drug proto-
cols.
Inadvertent inoculation is usually self-limited and no additional care
is needed. However, inoculations of the eye and eyelid require eval-
uation by an ophthalmologist and might require therapy with topical
antiviral or antibacterial medications, VIG, or topical steroids. 
GV is characterized by a disseminated maculopapular or vesicular
rash, frequently on an erythematous base, which usually occurs six
to nine days after first-time vaccination. This condition is usually self-
limited and benign, although treatment with VIG might be required
when the patient is systemically ill or found to have an underlying
immunocompromising condition. 
EV occurs among persons with a history of atopic dermatitis
(eczema), and is a localized or generalized papular, vesicular, or
pustular rash, which can occur anywhere on the body, with a
predilection for areas of previous atopic dermatitis lesions. Patients
with EV are often systemically ill and usually require VIG. 
PV is a rare, severe, and often fatal complication among persons
with immunodeficiencies, characterized by painless progressive
necrosis at the vaccination site with or without metastases to distant
sites (e.g., skin, bones, and other viscera). This disease carries a
high mortality rate, and management of PV should include aggres-
sive therapy with VIG, intensive monitoring, and tertiary-level sup-
portive care. 
Central nervous system disease, which includes postvaccinial
encephalopathy (PVE) and postvaccinial encephalomyelitis (or
encephalitis) (PVEM), can occur after smallpox vaccination. PVE is
most common among infants aged <12 months. Although no specif-
ic therapy exists for PVE or PVEM, supportive care, anticonvulsants,
and intensive care might be required. 
Fetal vaccinia, resulting from vaccinial transmission from mother to
fetus, is a rare, but serious, complication of smallpox vaccination
during pregnancy or shortly before conception. It is manifested by
skin lesions and organ involvement, and often results in fetal or
neonatal death. It is recommended that pregnancy be avoided until
28 days after vaccination. Pregnant individuals who are considering
vaccination (and pregnant spouses of vaccinated personnel) should
be made aware of this risk.
Making the Diagnosis
Conditions easily confused with vaccinia infection (i.e. varicella, her-
pes zoster, herpes simplex, and enteroviruses), should be consid-
ered first, in particular for someone who has not been vaccinated or
had contact with an individual who was vaccinated. 
Serologic testing for vaccinia is uninformative because it cannot be
used to distinguish vaccinia immunity from vaccinia infection unless
baseline antibody titers are available. 
Diagnostic tests for vaccinia are available only for research purpos-
es, but are undergoing multicenter validation studies that might
enable FDA to approve the test reagents for diagnostic use. 
Prophylaxis for Those at High Risk
Prophylactic treatment with VIG is not recommended for persons or
close contacts with contraindications to smallpox vaccination who
are inadvertently inoculated or exposed.
Reporting adverse events
Suspected cases of these illnesses or other severe adverse events
after smallpox vaccination should be reported immediately to state
health departments and to the Vaccine Adverse Event Reporting
System. Reports can be made online at https://secure.vaers.org/
VaersDataEntryintro.htm. To request clinical consultation and IND
therapies for vaccinia-related adverse reactions for civilians, contact
your state health department or the CDC's Clinician Information Line
(877-554-4625). Those with suspected adverse events should be
removed from work until evaluated and cleared to return.  
Timing of Tuberculosis Screening and Smallpox Vaccination
Suppression of tuberculin skin test (TST) reactivity has been demon-
strated after administration of smallpox vaccine. Health care workers
scheduled to receive an annual TST should not receive the skin test
for one month after smallpox vaccination to prevent possible false-
negative reactions.
Smallpox Resources
w Smallpox vaccination overview for clinicians:
http://www.bt.cdc.gov/agent/smallpox/vaccination/clinicians.asp
w Clinical evaluation tools:
http://www.bt.cdc.gov/agent/smallpox/vaccination/clineval. 
w Clinical specimen collection guidance:
http://www.bt.cdc.gov/agent/smallpox/vaccination/
vaccinia-specimen-collection.asp. 
w CDC Clinician Information Line:877-554-4625
w Center for the Study of Bioterrorism:
http://www.bioterrorism.slu.edu/
w Johns Hopkins Center for Civilian Biodefense
Strategies:http://www.hopkins-biodefense.org/
Smallpox Alert... (continued from page 5)
DISCLOSURES:  Nothing to disclose.
FOOTNOTES:
1. CDC. Vaccinia (Smallpox) Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR 2001
Jun 22; 50(No. RR-10):1-25.
2. Recommendations for Using Smallpox Vaccine in a Pre-Event Vaccination Program. 
Supplemental Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices
Advisory Committee (HICPAC). MMWR 2003 Feb 26; 52(Dispatch):1-16.
3. CDC. Smallpox Vaccination and Adverse Reactions: Guidance for Clinicians. MMWR 2003 Feb 21; 52(No.RR-4):1-28.
Discussion: It is difficult to determine the cause of liver toxicity in
HIV/HCV co-infected patients on HAART. Ritonavir may be the most
common cause of antiretroviral-related hepatoxicity, but all antiretro-
virals can damage the liver. Regardless of the etiology, HAART
should be continued in this patient given the mild transaminitis and
no evidence of synthetic dysfunction. Given the high rate of HBV and
HCV co-infection in HIV-infected patients, and particularly among
incarcerated persons, it is incumbent upon the provider to rule out an
infectious etiology as was done with this patient. It is controversial
whether RIBA confirmation is necessary with positive EIAs in high-
risk patients, given that new-generation EIAs have high positive pre-
dictive value in high-risk patients such as this one. 
What if this patient had screened EIA negative?
A recent study published in JAIDS1 reported that between 6% and
19% (depending on the HCV RNA method used) of HIV-infected
HCV antibody-negative patients had HCV viremia. HCV viremia in
persons without HCV antibodies was associated with HIV acquisition
through sexual contact as opposed to parenteral risk factors and
lower CD4 lymphocyte count. Most experts recommend follow-up
HCV RNA in all HIV-infected patients who screen HCV antibody
negative, but are still suspected of harboring HCV infection.
Another reason to do a follow-up HCV RNA is that up to 10% of
patients infected with HCV actually clear the virus (HCV antibody
positive and RNA negative) although the rate appears lower in
HIV/HCV co-infected patients. 
I would suggest checking the liver enzymes in one month and, if sta-
ble, checking every two to three months thereafter. Also continue to
monitor his T cell subsets, HIV RNA, kidney function, glucose and
electrolytes every three months if they all remain stable. I would
advise periodically monitoring a fasting lipid panel.
An important early step is to obtain HAV and HBV serologies, as was
done in this case. HCV-infected persons are at higher risk of going
on to fulminant hepatic failure if they contract HAV or HBV than are
people who do not have HCV infection. Therefore, those who have
not had prior infection should be vaccinated.
Why not just vaccinate against both hepatitis A and B and save
the cost of the serologies?
That strategy would be fine for HAV, but not for HBV. HAV has no
chronic carrier state, but providers must rule out chronic active
hepatitis B (hepatitis B surface antigen positive). Given that this
patient was negative for HAV antibodies, he was then vaccinated
against HAV.
Should hepatitis C treatments be discussed next?
This patient has several other issues that need to prioritized and
dealt with prior to even discussing treatment for HCV. He should be
educated regarding HCV infection transmission, just as one would
with someone who initially tests positive for HIV infection.
Contaminated needles associated with IDU account for the majority
of HCV infections in the developed world. Since 1992, at least two-
thirds of new cases of HCV infection in the United States can be
attributed to IDU. Although HCV was originally presumed to not be
readily transmitted by sexual contact, there is mounting evidence
that HCV is transmitted via sexual contact and HCV RNA has been
detected in semen, vaginal secretions, and saliva, though whether
the virus is replication-competent in these sites is not known.
Sharing of razors and toothbrushes should be strongly discouraged
given their potential for being contaminated with blood. 
The next step would be to discuss the natural history of HCV with the
patient, including that he is likely to have some liver damage, the
extent of which is unknown. Although most people do not go on to
end-stage liver disease with cirrhosis, this patient should be warned
of the hazards of alcohol abuse and HCV. 
The provider should explain that HIV accelerates the progression of
HCV, and that cirrhosis and mortality rates are higher in co-infected
patients than they are with HCV alone. 
The provider can then discuss available treatments. Co-infected
patients, especially with high CD4+ T cell counts, have been shown
to have similar treatment response rates compared to people with
HCV only. This individual's short incarceration period does not make
him a good candidate to initiate the current optimal treatment - pegy-
lated interferon and ribavirin for 6-12 months dependent upon HCV
genotype. I would advise discussing the options available to him and
would attempt to help him enter into the health care system in the
community prior to his release.
This patient's co-morbid mental illness should be addressed.
Incarcerated men and women have much higher rates of depression
and other mental illnesses than the general population. Untreated
depression is clearly correlated with poor adherence to antiretrovi-
rals and is a relative contraindication to interferon therapy for HCV.
REFERENCE:
1. Journal of Acquired Immune Deficiency Syndrome. 2002 Oct
1;31(2):154-62.
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Case presented and discussed by Stephen Tabet, MD, MPH, Assistant Professor of Medicine, University of Washington, and Director, Northwest
Correctional Medicine Education Program.
A collaboration with the Northwest AIDS Education and Training Center, with Stephen Tabet, MD, and Kate Willner.
Ask the Expert: Case Study – 36-year-old male with hepatitis C and HIV infection
Case: A 36-year-old bisexual male with B3 HIV disease is expected to be incarcerated for nine months. On intake, the CD4 lymphocyte
cell count is 542 cellsmm (31%), up from a nadir of 240 (17%), with an HIV bDNA < 50 copies/ml. He is currently on d4T 40 mg bid, 3TC
150 mg bid, and nelfinavir 1250 mg bid and has never had any opportunistic infections. He denies any injection drug use (IDU), but does
report a remote history of brief intranasal cocaine use. He is found on screening laboratory testing to have mildly elevated liver enzymes
(AST 76 and ALT 91) with normal LDH, bilirubin, albumin, prothrombin time, hematocrit, and platelet count. He reports symptoms of depres-
sion (difficulty sleeping, decreased appetite, and anhedonia) and appears depressed. The examination is otherwise normal; in particular
there is no evidence of spider angioma or palmar erythema. The provider screens the patient for hepatitis; an enzyme immunoassay (EIA)
shows that the patient tests positive for hepatitis C virus (HCV) antibody and hepatitis B (HBV) core and surface antibody, but negative for
hepatitis A (HAV) antibody.
What would you do for this patient? Should HAART be stopped?
9th Annual Jail Health
Conference
May 12-13, 2003
Wisconsin Dells, Wisconsin
Call: 715-836-3636
Email: ce@uwec.edu 
Visit: http://www.uwec.edu/CE/
American Correctional
Association Summer
Conference
August 9-13, 2003
Nashville, Tennessee
Call: 800-222-5646, ext. 1922
Visit: http://www.aca.org/
conventions/conventions_
2003_summer.htm
3rd Annual Intensive Review in
Correctional Medicine
Sponsored by the Correctional
Medicine Institute (CMI), the
Society for Correctional Physicians
(SCP), and Johns Hopkins
University
September 4-6, 2003
Baltimore, Maryland
Baltimore Marriott Waterfront Hotel
Call: 314-607-1565
Email: admin@cm-institute.org
Visit: http://www.cm-institute.org/
43rd Interscience Conference
on Antimicrobial Agents and
Chemotherapy (ICAAC)
September 14-17, 2003
Chicago, Illinois
Call: 202-737-3600
Email: icaac@asmusa.org
Visit: www.icaac.org/ICAAC.asp
The United States Conference
on AIDS
Sponsored by the National
Minority AIDS Council
September 18-21, 2003
New Orleans, Louisiana
Call: 202-483-6622
Visit: www.nmac.org
National Conference on
Correctional Health Care
October 4-8, 2003
Austin, Texas
Call: 773-880-1460
Visit: www.ncchc.org
41st Annual Meeting of
Infectious Disease Society of
America (IDSA)
October 9-12, 2003
San Diego, California
Call: 703-299-0200
Email: info@idsociety.org
Visit: www.idsociety.org
Save the 
Dates
8
CDC Issues Health Alert for SARS
The Centers for Disease Control and Prevention
(CDC) has issued a health alert for Severe Acute
Respiratory Syndrome (SARS), a new respiratory
illness apparently originating in Asia and now
reported in several countries. The illness usually
begins with a fever, chills, headache, myalgias and
malaise, followed by a respiratory phase charac-
terized by a dry, nonproductive cough and dysp-
nea. Persons with these symptoms who have trav-
eled recently to Hong Kong, Guangdong Province
in China; Hanoi, Vietnam, and Singapore; or their
close contacts (if symptomatic); may be at risk and
should be reported to the CDC. For more informa-
tion, go to http://www.cdc.gov/ncidod/sars/.
CDC, 3/22/03
NY Lawmakers Push for Oversight of Inmates'
Health
A package of bills that would extend New York
State Department of Health Oversight to reviewing
AIDS and hepatitis C care in prison facilities
passed New York's Assembly Health Committee.
Similar efforts in the past have failed, mainly for the
lack of a majority sponsor in the Republican-domi-
nated Senate. New York's Commission of
Corrections, a watchdog group, is currently
charged with establishing minimum health care
standards for inmates, but critics charge that the
prison system exists mostly without oversight,
resulting in inconsistent care. Corrections officials
maintain that what they are doing works and point
to the decline of AIDS-related deaths and TB out-
breaks in prisons in the last decade.
Associated Press, 3/23/03
HHS Announces Contracts to Develop "Safer"
Smallpox Vaccines
Health and Human Services officials announced
two contracts for the development of "safer" small-
pox vaccines that could be used to protect people
with compromised immune systems, including
p ople with HIV/AIDS. The administration agency
discourages people with HIV/AIDS, eczema, atopic
dermatitis and cancer, heart disease, as well as
pregnant women and organ transplant recipients
from receiving the current smallpox vaccine.
Kaiser Daily Reports, 2/27/03
HIV Serostatus Affects Rearrest Rates of 
Ex-prisoners
Researchers at the University of Washington pre-
sented results of a study contending that inmates
with HIV infection are more likely to be rearrested
upon release than HIV-negative inmates. Fifty-
seven HIV-positive inmates were compared to 254
HIV-negative inmates at the King County
Correctional Facility in Seattle, Washington. Using
the log rank test in Kaplan-Meier survival analysis,
statistical difference in the relative risk of rearrest
occurred for the HIV-positive group, according to
investigators. The full report, "Rearrest: Does HIV
Serostatus Make a Difference?" was published in
AIDS Care - Psychological and Socio-Medical
Aspects of AIDS/HIV (2002;14(6):839-849).
AIDS Weekly, 2/10/03
Prisoners Not Entitled to Hepatitis Treatment,
Court Rules
T e Montana Supreme Court denied prisoner
Keith Brown's petition for hepatitis C (HCV) med-
ication and returned the case to a lower court
recently. The divided court said it needed an official
determination of whether the diagnosis was cor-
rect. The court also asked for a determination on
whether there is an effective treatment for HCV. In
Montana, about 30 percent of the state's 2,750
inmates have hepatitis, according to the state's
DOC chief medical officer. 
Associated Press, 3/01/03
Inside News
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Resources & Websites
Society of Correctional Physicians
http://www.corrdocs.org
National Institute of Corrections
http://www.nicic.org  
CDC 2002 STD Treatment Guidelines: Pocket
Guides and Wall Charts
https://www2.cdc.gov/nchstp_od/piweb/
stdorderform.asp
Pocket guide summaries and wall charts of
CDC's 2002 STD Treatment Guidelines can be
ordered online. 
Pros & Cons:  A Guide to Creating Successful
Community-based HIV/AIDS Programs for
Prisoners
http://www.pasan.org
By Rick Lines, Prisoners HIV/AIDS Support
Action Network (PASAN), Toronto, Canada
This guide, available in English and French, pro-
vides background information on the prison sys-
tem, service/program ideas, and advocacy strate-
gies to create community-based HIV/AIDS pro-
grams for prisoners with the goal of better
defending the rights of prisoners and expanding
the availability and accessibility of HIV/AIDS ser-
vices. Includes chapters on the Prisons 101, HIV
and Hepatitis C in Prison, Getting Started, HIV
Prevention Education and Outreach, and Client
Support and Advocacy. It also contains an exten-
sive Resource section.
The guide can be downloaded, and single copies
(sent by mail) are free. Orders for multiple copies
or shipping outside of Canada must be pre-paid. 
To obtain Pros & Cons, contact:
Canadian HIV/AIDS Clearinghouse
400-1565 Carling Avenue, Ottawa, ON, K1Z  8R1
Toll Free: 1-877-999-7740
Tel. (613) 725-3434
E-mail: aidssida@cpha.ca
http://www.clearinghouse.cpha.ca 
Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through October 31, 2003. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. The smallpox vaccine is made from the variola virus, the
causative agent of smallpox.
(a) True
(b) False
2. Unintended transmission of the smallpox virus can occur:
(a) Immediately after vaccination up to a period of a week
(b) Immediately after vaccination until the scab separates 
from the skin two to three weeks later.
(c) Two days after vaccination until the scab separates from 
the skin two to three weeks later.
(d) Two days after vaccination up to a period of one month.
3. Since smallpox transmission occurs through contact with the
vaccination site, steps that should be taken to prevent contact
transmission are:
(a) Consistent hand hygiene with antimicrobial soap and 
water or an approved alcohol-based hand-rub containing 
more than 60% alcohol.
(b) Covering the vaccination site with gauze dressing and a 
semipermeable membrane.
(c) Wearing clothing that completely covers the vaccination 
site.
(d) Changing the dressings daily.
(e) All of the above.
4. Pregnant women are at no increased risk from the smallpox
vaccine.
(a) True
(b) False
5. An adverse reaction to the smallpox vaccine that might require
further evaluation or treatment include:
(a) Fever
(b) Headache
(c) Local skin reactions
(d) Inadvertent inoculation of the eye or eyelid
6. The CDC's Advisory Committee on Immunization Practices
recommends routine administrative leave for newly vaccinated
health care personnel for the duration of:
(a) One week
(b) Three weeks
(c) Four weeks
(d) Only in cases where an individual is physically unable to 
work because of symptoms; has extensive skin lesions that 
cannot be adequately covered; or is unable to adhere to the 
recommended infection-control precautions.
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
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HEPP Report Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1      
Inside News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP Report helps you in your work?
Why or why not?
3. What future topics should HEPP Report address?
4. How can HEPPReport be made more useful to you?
5. Do you have specific comments on this issue?
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